Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
very Fat dildos!
Popular Articles

Alkermes Initiates Two New Clinical Trials Of ALKS 33
Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of two new clinical trials of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other nervous system disorders. Study ALK33-004 is a phase 1 clinical trial designed to examine the ability of ALKS 33 to block the effects of an opioid following a single oral dose of ALKS 33 in healthy, non-dependent, opioid-experienced subjects. Study ALK33-003 is a phase 1 clinical trial designed to evaluate the pharmacokinetics, safety and tolerability of multiple doses of ALKS 33 in healthy volunteers.
diet pills Prezzi dentisti croazia
President's Remarks Point To Value Of Pharmacists On Patient Care Teams
In remarks on health care reform to the American Medical Association"s (AMA) House of Delegates on Monday, President Barack Obama pointed to pharmacists" participation on "multidisciplinary rounds" as an "island of excellence" that should become the "standard in our health care system."
News of the day
GI Disorders: Advances Being Made With Monoclonal Antibodies
Monoclonal antibodies can be safely and successfully used for the treatment of several gastroenterological disorders according to data being presented at Digestive Disease Week® (DDW®) 2009. DDW is the largest international gathering of physicians and researchers in the field of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
Health Insurance

Study Examines 'Elite' Group Of HIV-Positive People Who Appear 'Protected' From Developing AIDS

An international contingent of nearly 500 researchers and physicians are taking part in the International HIV Controllers Study, which is examining "the phenomenon," in which certain people living with HIV seem "somehow protected from AIDS," the Washington Post reports. Fewer "than one in every 300 cases, or perhaps 5,000 of the more than 1 million infected Americans" living with HIV are deemed ""elite controllers" because their ability to combat the virus puts them in exceptional company among infected individuals," according to the Post. The article states, "No one knows how their bodies keep AIDS at bay. Are their immune systems exceptionally strong and effective? Do they possess some genetic trait that protects them? Or does a combination of still-unknown factors set them apart?" Researchers anticipate that studying the T cell levels - which helps determine the progression to AIDS - of the elite controllers, will enable them "to uncover what shields these rare few from AIDS. And perhaps in the process they"ll find a way to safeguard everyone else as well," the Post reports (Slack, 7/7). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009